Rocuronium
Propofol Adverse Reaction
Zhejiang Cancer HospitalPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Propofol Adverse Reaction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PROPOFOL Zhejiang Cancer Hospital | Phase 2 | B |
Same molecule, other indications
Rocuronium is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →